Evidence map›Paper›PMID 31471761›Full record

ReviewCurrent diabetes reports2019

Cytosine Methylation Studies in Patients with Diabetic Kidney Disease.

Tamas Aranyi, Katalin Susztak

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Update: the role of epigenetics in the metabolic memory of diabetic complications.American journal of physiology. Renal physiology · 2024
    Review
  4. The therapeutic effect of mesenchymal stem cells in diabetic kidney disease.Journal of molecular medicine (Berlin, Germany) · 2024
    Review
  5. Metabolic memory: mechanisms and diseases.Signal transduction and targeted therapy · 2024
    Review
  6. Article
  7. Molecular pathways that drive diabetic kidney disease.The Journal of clinical investigation · 2023
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Tamas AranyiRenal Electrolyte and Hypertension Division, Department of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, 12-123 Smilow Translational Research Building, Philadelphia, PA, 19104, USA.
Katalin SusztakRenal Electrolyte and Hypertension Division, Department of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, 12-123 Smilow Translational Research Building, Philadelphia, PA, 19104, USA. ksusztak@pennmedicine.upenn.edu.
University of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of the reviewKidney disease is the major cause of morbidity and mortality in patients with diabetes. Poor glycemic control shows the strongest correlation with diabetic kidney disease (DKD) development. A period of poor glycemia increases kidney disease risk even after an extended period of improved glucose control-a phenomenon called metabolic memory. Changes in the epigenome have been proposed to mediate the metabolic memory effect, as epigenome editing enzymes are regulated by substrates of intermediate metabolism and changes in the epigenome can be maintained after cell division. RECENT

findingsEpigenome-wide association studies (EWAS) have reported differentially methylated cytosines in blood and kidney samples of DKD subjects when compared with controls. Differentially methylated cytosines were enriched on regulatory regions and some correlated with gene expression. Methylation changes predicted the speed of kidney function decline. Site-specific methylome editing tools now can be used to interrogate the functional role of differentially methylated regions. Methylome changes can be detected in blood and kidneys of patients with DKD. Methylation changes can predict future kidney function changes. Future studies shall determine their role in disease development.

Indexed as

CytosineDiabetic NephropathiesDNA MethylationEpigenesis, GeneticEpigenomeHumansKidneyCytosineCytosine methylationDiabetic kidney diseaseEpigeneticsEpigenome editingEpigenome-wide association analysis (EWAS)Metabolic memory

Identifiers

PMID31471761
OpenAlexW2970792565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.